Transjugular intrahepatic portosystemic shunts vs Conventional treatment
All‐cause morbidity · adults with hepatorenal syndrome
Transjugular intrahepatic portosystemic shunts showed no clear difference in morbidity due to any cause compared with conventional treatment (low certainty).
1 finding from 1 review
- Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes onlyRR 0.95 [0.77, 1.18]2 studies · 130 participantsLow